Last updated: February 17, 2026
What is the current market position of NDC 00832-1410?
NDC 00832-1410 is marketed as Atenolol 50 mg tablets, primarily used for managing hypertension and certain cardiac conditions. It holds a significant share in the beta-blocker segment, with widespread prescription patterns in the United States, according to IQVIA data (Q4 2022). The drug faces competition from generics and other beta-blockers like metoprolol and propranolol.
What is the market size and sales volume for Atenolol 50 mg?
The US retail sales of Atenolol in 2022 reached approximately $120 million. The volume of units sold declined by roughly 12% from 2021, reflecting a shift toward newer agents like bisoprolol and carvedilol. Leading generic manufacturers dominate the space, capturing over 75% of total sales, with Teva, Mylan, and Sandoz being prominent players.
What are the key factors influencing pricing trends?
Pricing for Atenolol 50 mg has exhibited a declining trend over the past five years, with average wholesale prices (AWP) decreasing by approximately 30%. The competitive generic landscape, increased market penetration, and safety data favoring newer beta-blockers contribute to this decline. The list price of a typical 30-day supply averages $15–$20 retail, but actual transaction prices are significantly lower due to discounts and payer negotiations.
How do regulatory and patent landscapes impact pricing and market dynamics?
Atenolol has been off-patent since 2005, enabling broad generic manufacturing. Absence of patent protections and high generic competition suppress prices. The entry of biosimilar-like polypeptides is unlikely due to the drug's small molecule nature, leaving generics as the primary price determinant. Recent FDA approvals of newer antihypertensive classes have also reduced Atenolol’s market share.
What are medium- and long-term price projections?
Over the next five years, US retail prices for Atenolol 50 mg are projected to decline further by an additional 10–15%, based on historical price trends, increasing generic competition, and market shifts toward newer therapies. The median retail price around $10–$15 for a 30-day supply could be expected by 2028.
In the broader context, annual sales are likely to decrease at an annual rate of 4–6%, driven by declining prescriptions as clinicians favor drugs with better side-effect profiles and newer mechanisms of action. However, in specific markets such as low-income regions or among patients with contraindications to newer agents, demand may sustain.
How is the global market expected to evolve?
Outside the US, emerging markets such as India, Brazil, and parts of Southeast Asia still use Atenolol extensively. In these regions, pricing remains lower, typically in the range of $3–$8 per 30-day supply, with minimal patent influence due to early patent expiration. Market growth is limited by generic saturation and local healthcare policies.
Summary table
| Aspect |
Data |
Trends/Comments |
| Current market size in US |
~$120 million (2022) |
Declining due to generic competition |
| Price per 30-day supply (US retail) |
$15–$20 |
Decreasing trend, expected to drop further |
| Market share of top generics |
75%+ |
Consolidation among top players |
| Price decline over 5 years |
~30% |
Driven by competition, patent expiry |
| Projected price in 5 years |
$10–$15 |
Continued decline expected |
Key Takeaways
- Market size: Significant but declining due to generics and shifting prescriptions.
- Pricing trajectory: Prices are decreasing, with 2022 average retail (~$15–$20) expected to fall to ~$10–$15 in five years.
- Competitive landscape: Dominated by large generics manufacturers with minimal patent influence.
- Global variation: Lower prices in emerging markets; little growth expected outside mature markets.
- Long-term outlook: Prescriptions decline, but demand persists in specific sectors and regions.
FAQs
Q1. What factors most influence the future price of NDC 00832-1410?
Generic competition, healthcare policy changes, and prescriber preferences for newer agents. Patent expiry and biosimilar entry are less relevant due to the drug’s formulation.
Q2. How does market share impact pricing?
Dominant generics benefit from economies of scale, enabling further price reductions. Smaller producers may struggle to maintain margins, accelerating price declines.
Q3. Could patent or exclusivity issues re-emerge?
Unlikely, as the product has been off-patent for over 15 years. No current patent protections are in place.
Q4. How are payer negotiations affecting prices?
Payer negotiations and formulary placements influence actual transaction prices, often below wholesale prices, especially with high-volume generic competition.
Q5. What regions present growth opportunities for Atenolol?
Emerging markets where brand penetration is limited and regulation favors low-cost generics. Local market dynamics will determine growth potential.
Sources:
[1] IQVIA, 2022. Health Care Product Sales Data.
[2] U.S. Food and Drug Administration (FDA). Drug Approvals and Patent Data, 2022.
[3] Medispan, 2022. Drug Pricing Trends.
